報價延遲最少15分鐘:2026/05/06 22:19 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
84.54 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.22/-5.39
|
|
企業價值
6.28B
|
| 資產負債 |
|
每股賬面淨值
12.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for thetreatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies bytargeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
